Genetic research could reduce market for cancer drugs

06/1/2008 | Wall Street Journal, The

Studies on the potential of the K-ras gene for personalized medicine could help doctors determine which cancer drugs will most likely benefit patients, but they also threaten to shrink the market size for such treatments, some drugmakers and scientists said. Companies are acknowledging that a smaller market for some treatments in exchange for improved patient outcomes will produce good results. "It will be a better approach, and I think everyone is going to be adopting it," said Pfizer's head of oncology development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC